Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

[1]  T. Powles,et al.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.

[2]  C. Blomqvist,et al.  Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients , 2004, Acta oncologica.

[3]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[4]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Mundy.  Preclinical models of bone metastases. , 2001, Seminars in oncology.

[6]  I. Diel.  Bisphosphonates in the prevention of bone metastases: current evidence. , 2001, Seminars in oncology.

[7]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[9]  T. Powles,et al.  Clodronate decreases the frequency of skeletal metastases in women with breast cancer. , 1996, Bone.

[10]  G Marini,et al.  Effect of systemic adjuvant treatment on first sites of breast cancer relapse , 1994, The Lancet.

[11]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[12]  C. Galasko.  Mechanisms of bone destruction in the development of skeletal metastases , 1976, Nature.

[13]  T. Powles,et al.  The Inhibition by Aspirin and Indomethacin of Osteolytic Tumour Deposits and Hypercalcaemia in Rats with Walker Tumour, and its Possible Application to Human Breast Cancer , 1973, British Journal of Cancer.

[14]  J. Gralow.  Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease , 2005 .

[15]  T. Powles,et al.  Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients , 2003, Drug safety.

[16]  R. Rubens,et al.  Clinical course and prognostic factors following bone recurrence from breast cancer. , 1998, British Journal of Cancer.

[17]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.